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Abstract A novel estrogen receptor (hereinafter referred to as pounds which may be effective in estrogen-dependent thera- 
ER~) was cloned using degenerate PCR primers. A comparison pies such as hormone-replacement therapy and cancer. 
of the amino acid sequence of ER[~ with the 'classical' ER (ERa) Here, we report the identification and characterization f a 
shows a high degree of conservation of the DNA-binding domain novel human estrogen receptor (designated ER~), which is 
(96%), and of the ligand-binding domain (58%). In contrast, the highly homologous with the 'classical' ERa  and has an over- 
A/B domain, the hinge region and the F-domain are not lapping but non-identical tissue distribution. We demonstrate 
conserved. Northern blot analysis revealed that ER[~ is expressed that this novel receptor is functional in that it interacts with 
in human thymus, spleen, ovary and testis. Transient transfec- (anti-)estrogens and is able to modulate estrogen-responsive 
tions of an ER[~ expression construct together with an ERE- reporter gene expression. 
based reporter construct in CHO cells clearly demonstrated 
transactivation of ER[~ by 17~estradiol. In addition, the ERa 
antagonist ICI-164384 is a potent antagonist for ER[~ as well. 2. Materials and methods 
Interestingly, the level of transactivation by 17[~-estradiol is 
higher for ERa than for ER[~, which may reflect suboptimal 2.1. RT-PCR, RACE-PCR andprimers 
conditions for ER[~ at the level of the ligand, responsive lement One microgram of total RNA (from EBV-stimulated human per- 
or cellular context, ipheral blood leukocytes) was reverse transcribed in a 20 ~tl reaction 
containing 50 mM KC1, 10 mM Tris-HC1 pH 8.3, 4 mM MgC12, 
Key words." Estrogen receptor; 17[~-Estradiol; Anti- 1 mM dNTPs (Pharmacia), 100 pmol random hexanucleotides (Phar- 
estrogens; Transactivation; Human macia), 30 units RNase inhibitor (Pharmacia) and 200 units M-MLV 
reverse transcriptase (Gibco BRL) at 37"C for 30 min followed by 
5 min at 100°C. Two degenerate oligonucleotides were based on con- 
1. Introduction served regions of the DNA-binding domains (primer 1) and the li- 
gand-binding domains (primer 2) of the human steroid hormone re- 
ceptors. PCR reactions (100 ~tl) contained 10 mM Tris-HC1 pH 8.3, 50 
The estrogen receptor (ERa) is a member of the superfam- mM KCI, 1.5 mM MgCI2, 0.001% gelatine (w/v), 3% DMSO, 1 ktg of 
ily of nuclear receptors which are able to transduce xtracel- each primer and 2.5 units of Amplitaq DNA polymerase (Perkin 
lular signals (small lipophilic molecules) into transcriptional Elmer). The PCR protocol was: 4 rain at 94°C, then 36 cycles (30 s 
responses [1]. In general, nuclear receptors have a modular 94°C, 30 s 45°C, 1 min 72°C) and finally 7 min at 720C. All other 
PCR reactions were performed with an annealing temperature of 55°C 
structure with six distinct regions, A-F .  Of these, region C and with 200 ng of each primer. Fragments of interest were cut out of 
(corresponding to the DNA-binding domain) and region E a 1.5% agarose gel, reamplified and cloned using the TA-cloning kit 
(corresponding to the ligand-binding domain) are evolution- (Invitrogen) and sequenced using a T7 DNA sequencing kit (Pharma- 
arily conserved [2]. Steroid hormone receptors are distinct cia). 
from other nuclear eceptors in a number of respects including RACE (rapid amplification of cDNA ends) PCR reactions were 
performed using a Marathon-ready kit (Clontech) with testis cDNA 
the nature of their ligands, their association (in the unliganded as template. 
state) with a repertoire of heat-shock proteins, and the fact 
that they bind to hormone response lements as homodimers Primer 1: 5'-GGIGA(C/T)GA(A/G)GC(AFF)TCIGGITG(C/T)C- 
[3]. Since the cloning of the ERa  cDNA [4,5], a great deal of A(C/T)TA(C/T)\GG-3' 
detailed knowledge regarding its mechanism of action has Primer 2: 5'-AAGCCTGG(C/G)A(C/T)IC(Gfr)(C/T)TTIGCC- 
CAI(C/T)TIAT-Y 
been obtained (see e.g. [6-8]). Basically, ERa  dimerizes Primer 3: 5'-TGTTACGAAGTGGGAATGGTGA-Y 
upon ligand binding and the homodimer then binds to estro- Primer 4: 5'-GGC(C/G)TCCAGCATCTCCAG(C/G)A(A/G)CA- 
gen response lements (EREs) in the transcriptional control G-Y 
regions of target genes. In addition, a number of pathways are Primer 5: 5'-TCTTGTTCTGGACAGGGATG-Y 
Primer 6: 5'-GGAAGCTGGCTCACTTGCTG-Y 
now known to influence ER functioning: e.g. different con- 
formations induced by different ligands, modifications of the 
receptor by phosphorylation and interactions of the receptor 2.2. Northern blot analysis 
with other transcription factors [8-10]. In recent years, ERa  Human multiple tissue Northern blots (Clontech) were prehybri- 
dized for at least 30 min at 65°C in 0.5 M phosphate buffer pH 7.5 
has become an important arget for the identification of com- with 7% SDS. A ER~-specific PCR fragment was generated using 
primer 2 in combination with primer 3. This probe was 32p-labelled 
using a Decaprime kit (Ambion), denatured by boiling, added to the 
prehybridization solution and incubated overnight at 65°C. Washing 
conditions were: 3 × SSC at room temperature, followed by 3 × SSC at 
*Corresponding author. Fax: (31) (412) 662553. 65°C and then 1 × SSC at 65°C. 
The nucleotide sequence of the cloned human ER~ has been assigned 2.3. Cloning of ER~ 
the accession umber X99101. Approximately 400000 recombinant phages of a human testis 
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eDNA library in )~gtll (Clontech HL1010b) were screened. Replica 2.4. Cell culture, transient ransfeetions and transactivation assay 
filters (Hybond-N, Amersham) were made as described by the manu- Chinese hamster ovary cells (CHO K1; CCL61) were cultured in 
facturer and hybridized with the ERI3-specific probe (see Section 2.2). phenol red-free M505 medium (a 1:1 mixture of Dulbecco's modified 
Filters were prehybridized in a solution containing 0.5 M phosphate Eagle's medium (DMEM, Gibco) and nutrient medium F12 (Ham's 
buffer (pH 7.5) and 7% SDS at 65°C for at least 30 rain. Probe- F12, Gibco)) supplemented with 5% charcoal-treated bovine calf ser- 
labelling and hybridization were as described in Section 2.2. Filters um (Hyclone) and antibiotics. The ER[3 reading frame was cloned in 
were washed in 0.5×SSC/0.1% SDS at 65°C. Positive clones were the mammalian expression vector pNGV1, a modification of pKCR 
plaque-purified and fragments generated by PCR were cloned and [11] containing the SV40 early promoter and the IgG and MuLV 
sequenced. For verification of the nucleotide sequences the complete enhancers. The reporter expression vector was based on the rat oxy- 
eDNA insert was generated using the proof-reading Pfu polymerase tocin gene regulatory region position -363l+16 [12] linked to the 
(Stratagene), cloned and both strands were sequenced, firefly luciferase gene. CHO cells (1 × l05) were seeded in 6-well Nun- 
In order to clone sequences downstream of exon 7, primer 4, based clon tissue culture plates and DNA (1 ~tg of both receptor and re- 
on the ERc~ AF-2 region was used in combination with ERL3-specific porter constructs and 250 ng ~-galactosidase v ctor in 250 ~10pti- 
primer 5 (nucleotides 936-955 in Fig. 1A) and then nested with primer mere, Gibco BRL) was mixed with an equal volume of lipofectin 
6 (nucleotides 1130~1149 in Fig. 1A), using testis eDNA (Marathon- reagent (7 ~tl in 250 Ixl Optimem) and allowed to stand at room 
ready, Clontech) as template. A specific fragment was analyzed as temperature for 15 min. This solution was mixed (1:1) with Optimem 
described above. The remainder of the earboxy-terminus was cloned and 1 ml of this mixture was added to each well after washing the cells 
using RACE PCR reactions on the same testis eDNA. First primer 5 (serum-free M505). After a 5-h incubation the cells were washed 
was used together with the AP1 primer provided in the kit, then a (phenol red-free M505 with 5% charcoal-treated bovine calf serum) 
nested PCR was performed using primer 6 together with the CDS and incubated overnight at 37°C. After 24 h hormone was added to 
primer from the kit. Fragments that were obtained were cloned and the medium. 17J3-Estradiol (Org2317) was obtained from Organon, 
sequenced. Oss, The Netherlands, ICI-164384 was kindly provided by Dr. A.E. 
A GGCTATA~CCT~TGTG~TGAATT~A~ATTC~CA~TGTcAcT~CTT~TGGGCCT~T~GGCA~CCAC~C~AAATGTGTTGTGGC~AC~TGGC~CA~TTT~T 120 
G Y S P A V M N Y S I P S N V T N L E G G P G R Q T T S P N V L W P T P G H L S  34 
~TTTAGT~Tc~ATC~cAGTTAT~A~ATCTGTAT~c~T~AAAAGAGT~C~T~TGTG~GAT~TA~CACAccTTA~TGTAAACAGAGAGA~AcTGAAAA~G 240 
P L V V H R Q L S H L Y A E P Q K S P ¥ C E A R S L E H T L P V N R E T L K R K  74 
GTTAGTGGG~CCGTT~CA~CTGTTA~T~TC~A~TTCAAAGAGGGAT~TcACTT~T~TGTCT~A~GATTA~ATCGGGATAT~A~TAT~AGT~T~T~GTGTG~ 360 
V S G N R C A S P V T G P G S K R D A H F C A V C S D Y A S G Y H Y G V W S C E  114 
~ATGT~GGCCTTTTTTAAAAG~ATTC~ACAT~TGATTATATTTGTCCA~TAcAAATCAGTGTA~TcGATAAAAACCGGC~GA~T~AGGCCT~CGACTTC~ 480 
G C K A F F K R S I Q G H N D Y I C P A T N Q C T I D K N R R K S C Q A C R L R  154 
~GTGTTACG~GTGGG~T~TG~GTGTGGCT~CC~AGAGAGAGATGTGGGTACC~CTTGT~AGAc~AG~GT~GAcGA~A~T~ACTGT~CGGC~GC-C~GAGA 600 
K C Y E V G M V K C G S R K E R C G Y R L V R R Q R S A D E Q L H C A G K A K R  194 
AGTGGCGGCCAC~CCCGAGT~GGGA~T~T~T~CCTGA~CCcGA~A~TAGT~TCA~CTcCT~AGGCTGA~C~CCCATGT~TGATCA~c~CC~T~G 720 
S G G H A P R V R E L L L D A L S P E Q L V L T L L E A E P P H V L I S R P S A  234 
CCCTTCA~CGAGGCcTCCATGATGATGTCCcTGA~C~GTTGGCCGAC~AGTT~TACAcATGATCA~TGGGCcAAG~GATT~CGGCTTTGT~A~TCA~CTGTTCGA~C~ 840 
P F T E A S M M M S L T K L A D K E L V H M I S W A K K I P G F V E L S L F D Q  274 
GT~GGCTCTT~AGA~TGTT~AT~A~TGTT~TGATGGGGCTGATGTGGC~TC~TTGACCACCCcGGC~TCAT~TTT~Tc~AGAT~TTGTTCT~ACAGGGATGAGGG~ 960 
V R L L E S C W M E V L M M G L M W R S I D H P G K L I F A P D L V L D R D E G  314 
AAAT~GTAG~TTCT~AAAT~TTTGACAT~TCcTGGC~CTACTTC~TTTCGAGAGTTAAAACTCCAACACAAAG~TATCT~TGTGTC~GGCCAT~TCCT~TC~T 1080 
K C V E G I L E I F D M L L A T T S R F K E L K L Q H K E Y L C V K A M I L L N  354 
TCCAGTATGTACCCTCT~TCAcA~GA~A~AT~TGAcA~A~C~TGGCT~ACTT~TG~C~CGTGACCGAT~TTT~TTTGGGTGATT~C~GA~GC~CATCTCC 1200 
S S M Y P L V T A T Q D A D S S R K L A H L L N A V T D A L V W V I A K S G I S  394 
T~CCA~A~TC~AT~TGGCT~CCT~cTGAT~T~TGT~CcA~GTcAC~AT~GAGT~C~C~AT~CAT~T~TC~CATG~GT~AAAAATGT~TC~CAGTG 1320 
S Q Q Q S M R L A N L L M L L S H V R H A S N K G N E H L L N M K C K N V V P V  434 
TATGA~CT~T~T~AGAT~TG~T~CCACGT~TTC~C~T~GTccTcCATCACGGGGT~CGAGT~A~CCGGcAGA~ACAGTAAAA~A~GAGGGCT~C~AG~CC~A 1440 
Y D L L L E M L N A H V L R G C K S S I T G S E C S P A E D S K S K E G S Q N P  474 
cAGTCT~AGTGAC~TGGC~cTGA~TG~CTGC~C~CA~AGA~TCAC~TG~GTG~Tcc~TGTGT~A~A~CTGGGCTT~AT~TTTCT~TGTGT~TcCCTCATTT~ 1560 
Q S Q -  
ER~ - MTMTL~TKASGMALLHQI~NELEP~PQLKIPLE~P~E~LDSSKPAVYNYPEG~YEFNAAAAANAQ~TGL~YG~GSEAAAFGSNGLGGFPPL  - i00  
T i I III 
ER~ - ~YS IPS~ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  TNLE~PGRQTTSPNVL~TPGHLS -34 
ER~ - NSVSPSP~LLHPPPQLSPFLQPHGQQ~YYLENEPSGYT~EAGPP~YRPN~DNRRQGGRERLASTNDKGSMAMES~ET~Y~vCNDY~GYHYGvW -200 
I I I II II II i I I I I I I I I I I 111111 
ER~ -PLVVHRQLSHLYAEPQKSPWCE~SLE . . . . . . . . . . . . . . . . . . . . . . .  HTLP~RET~RKVSGNRC~P~GPGSK~F~YASGYHYGg~- I I I  
ER~ -S~C~FE~%~IQGRK~)~MCPA2NQCT~E~WR~K~c~G~K~I~DRR~L~KRQ~D~EGRGEVGSAGDMKAANL~SP~IK~-3~ 
l l l l l i i l l l l l l l l l i l l  1111111111111 i l l i l l l l l l l l l l l t l  I I I I I I I I I 
ER~ -SCEGCKA~FERS~QGR~NDYICPA-TNQ~Iq~RR-K~QACRI~CGSR~ERCGYRL~RQRS~EQLHCAGK~RS~HAPR~ . . . . . . . . . .  202 
ER~ SK~SLALSLTADQ~S~LD~PPILYSEYDPTRPFSE~GLLTNLAD~ELV~I~R~PGF~LTLH~LLECA~4LE I~IGLVwRSMEHPG-40~ 
I I I I II l i l l  I Jl I I I I I  II Ill I I I I I I  111 ll~J I I ill III I J II II lIJ Jll 
ER~ - - -RELLLD~SPEQLVLTLLEAEPPHVL IS -~PS~FTE~MMMSLTK I2~DKELVHMISWAKKIPGFVELSLF~RLLE~CWMEvLMMGLMwRSIDHPG -299 
ER~ - KLLFAPNLLLD~KCVEGMVEIFDML~TSSRFR~LQGEEFVCLKS I IL~SG~TFLSSTLKSLEE~HIHR~DKITDTL IH IMAKAGLTLQQQ -500 
II III I Ill I I I I I I  I I I I I I I I I  l l l J  II I i I I I I I I  I I I il I II i III 
ER~ -KL IF~DL~D~EGKCVEGILE IFDML~TTSRFKELKLQHKEYLCVK~IL~S~L~ATQDA-DSSRKLAHL~A~D~VWVI~SGISSQQQ-398 
ER~ - HQR~QLLL ILSHIRHMSNK~EHLYS~KNVVPLYDLLLEMLD~RLHAPTSR~ET~SH~TAGSTSSHSLQKYY ITGE~GFPATV -595 
III II III Jl l l J l l l l l  l l l l l l l l  I J l l l ] l l  II I I I il J 
ER~ - SMRLANL~LLSHVRHASNK~EHL~CKNVVP~DLLLEM~AHVLRGC~SITGSECSPAEDS~GSQNPQSQ -477 
Fig. 1. (A) Nucleotide sequence and deduced amino acid sequence of ER~. (B) Al i~ment of the amino acid sequences of the human ER~ with 
the human ERa. The DNA-binding domains are shown in bold, the consensus equence ~r  MAPK-mediated serine phosphorylation is under- 
lined and the F-domains are shown in italics. 
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Fig. 2. Tissue distribution of ER[3. Each lane contains 2 lag of poly A+ RNA isolated from the human tissues indicated at the top (PBL, per- 
ipheral blood leukocytes). RNA size markers are indicated on the left. 
Wakeling, Zeneca Pharmaceuticals, Macclesfield, UK. Cell extracts was cloned and sequenced. It was shown to contain the car- 
were made 48 h post-transfection bythe addition of 200 gl lysis buffer boxy-terminus of ER[3, including AF-2, an F-domain fol- 
(0.1 M Na2HPO4, 0.2% Triton X-100). 20 lal sample was added to 50 
I.tl luciferase assay reagent (Promega). Light emission was measured in lowed by a stop codon and part of the 3' untranslated region. 
a Topcount (Packard). Beta-galactosidase ctivity was measured using A comparison of the complete ER[~ and ERa amino acid 
a Galacto-light plus kit (Tropix) to correct for differences in transfec- sequences i shown in Fig. 1B. 
tion efficiency. The high degree of conservation of the DNA-binding do- 
main (96%) and the relatively high degree of conservation of 
3. Results the ligand-binding domain (58%), as compared to currently 
reported estrogen receptor-related receptors ERR1 and ERR2 
Using degenerate primers (see Section 2) we cloned a PCR [13], suggested that ERI3 could bind estrogenic hormones and 
fragment which corresponds to a novel receptor (designated activate transcription of ERE-containing promoters. To ex- 
ER[3) which is highly homologous with the classical estrogen perimentally test this hypothesis, CHO cells were transfected 
receptor (ERa). Part of this fragment (corresponding to nu- with an ERI3 (or ERa) expression construct ogether with a 
cleotides 484-815 in Fig. 1) was used as a probe to determine well-known ERa-responsive reporter plasmid (rat oxytocin 
the tissue distribution of ER[3 by Northern blot analysis. Fig. promoter-luciferase, RO-luc [14]) and treated with 17[~-estra- 
2 shows that ERI3 is expressed in thymus, testis and ovary diol. Fig. 3A clearly shows that ER[~ can activate transcrip- 
(approx. 8 kb and 10 kb transcripts) and very faintly also in tion of RO-luc in a hormone-dependent manner, although the 
spleen. In addition, a relatively abundant transcript of 1.3 kb level of induction is higher for ERa. In addition, ER[3 is able 
is present in testis. Screening of a human testis cDNA library to activate transcription of a reporter construct containing 
resulted in the identification of two identical positive clones three synthetic EREs (not shown). Fig. 3A also shows that 
which contained a large part of the ERI3 reading frame (nu- the ERa antagonist ICI-164384 (ICI) is a potent antagonists 
cleotides 1-1265 in Fig. 1A). At the 5' end, an in-frame ATG for both ERa and ERI3. Fig. 3B shows a dose-dependent 
codon (nucleotides 19-21) is present, but since the clone lacks transactivation f ERa and ER[3 by 1713-estradiol, indicating 
an in-frame stop codon further upstream, we cannot exclude that both receptors can be activated at very low hormone 
the possibility that upstream ATG translation initiation co- concentrations. However, half-maximal activation is reached 
dons may be present. At the 3' end, the homology with the at lower concentrations of 17[~-estradiol for ERa than for 
ERa is lost abruptly at a site which corresponds to the splice ERI3. 
site between exon 7 and exon 8 in ERa, suggesting that this 
cDNA is derived from an incompletely spliced transcript. In 4. Discussion 
order to obtain nucleotide sequences downstream of this 
splice site, tesUs cDNA (Marathon-ready, Clontech) was The current report describes the identification of ERI] as a 
used as a template to generate a RACE PCR fragment hat functional estrogen receptor which can interact with the re- 
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A restricted to thymus, spleen, ovary and testis. However, the 
20 - initial PCR fragment was cloned from peripheral blood lym- 
18 ~ phocytes, whereas no signal is detected on Northern blot. 
l=ER-be,a I Therefore, it may be that the sensitivity of Northern blot 
16 analysis is insufficient o detect ER~ expression in some tis- 
sues. It is not likely that the probe and the conditions used 
14 ~- allow hybridization with ERtx. Hybridization of the same 
.o 12 blots with a probe corresponding to part of the 3' untrans- 
lated region of ERct revealed a 6.5 kb band in almost all 
.=fi 10 tissues, especially ovary, testis, prostate and skeletal muscle 
to (not shown). The ligand-binding domain is relatively well con- 8 
o ~ served (58%) and our data demonstrate hat as a result, ERI3 
6 L closely resembles ERct with respect o the binding of 1713- 
estradiol and ICI-164384. This suggests that there is a high 
4 degree of structural conservation of the ligand-binding pock- 
2 et(s). Although both receptors interact with 1713-estradiol with 
high affinity, Fig. 3B suggests that ERt~ has a higher affinity 
0 ~ for this ligand than ERI3. The difference with respect o the 
no hormone E2 10-9 M ~ 10-9M level of induction may relate to the nature of the ligand, the 
+ IOI 10-6 M 
responsive lement or to the cellular context (co-activators/ 
B repressors), which may not have been optimal for ERI3 in 
10080 J ~ /  the current co-transfection assay. Although the DNA-binding 
90 + ER-alpha / ~ domain is extremely well conserved (96%), ERI3 and ERc~ may 
activate different sets of target genes. Since not only the P-box 
A + ER-beta but also the D-box is conserved, it can be envisaged that in 
I addition to forming homodimers, ER[3 and ERc~ may form C 
.~ I~ 70 heterodimers thereby influencing each other's transcriptional 
t activity. m ° ~ 60 The A/B domain, the hinge (domain D) and the F-domain 
~ are poorly conserved. Interestingly however, the ERI3 A/B ~'-** 50 
domain contains a consensus equence for MAPK-mediated 
~ 40 serine-phosphorylation (PQKSP in ER~, underlined in Fig. 
~ ] 1B) which is also present and functional in the ER~x A/B 
30 ~ I domain [16]. The lack of conservation of the A/B domain ~.~ 
a. ,,, 2 0 ~  suggests important differences between both receptors with 
~ ~ respect o their AF-1 activity and with respect o interactions 
10 of co-activators and/or repressors with this region. The lack of 
conservation of the F-domain is also striking in view of its 
0 suggested role in modulating the extent of the agonistic activ- 
o=° '7~' "7~' "-~" 6~" o~' 6g" o~" ity of compounds like 4-OH-tamoxifen i  ERcz [17]. 
In conclusion, the cloning of ERI3 adds to the complexity of 
o (tissue-specific) estrogenic effects. It can be envisaged that it 
will be worthwhile to dissect ERI3 pathways from ERc~ path- 
Concentration 17-beta estradiol (M) ways as well as to identify compounds which specifically inter- 
Fig. 3. (A) Effect of 1713-estradiol (E2) alone or in combination act with ERc~ or ERI 3. 
with the anti-estrogen ICI-164384 (ICI) on the transcriptional ctiv- 
ity of ERo~ (gray bars) and ER[3 (black bars) using an ERE-based Acknowledgements." The authors gratefully acknowledge Guido Jen- 
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